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To the Editor:
Long-term treatment with the second-generation tyrosine kinase inhibitors (2 ndG TKIs) nilotinib and dasatinib may result in cardiovascular (CV) complications. Accumulating evidence suggests that the combination of a median age at the time of chronic myeloid leukemia (CML) diagnosis of greater than 60 years, when CV adverse events (AEs) are common, and the CV toxicity of 2 ndG TKIs represents per se a potential predisposing factor, which requires preventive strategies and CV surveillance in patients with CML [1] [2] [3] .
Previous studies have suggested the usefulness of the Systematic Coronary Risk Evaluation (SCORE) assessment at disease baseline, a 10-year risk estimation of fatal CV disease based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels, to identify patients who are at heightened risk of CV AEs during nilotinib treatment [4] [5] . A preventive strategy with primary prophylaxis based on aspirin remains under discussion. We therefore analyzed a large real-life cohort of Italian patients with CML treated with a 2 ndG TKIs as first-or subsequent-line of treatment. The primary objective was to evaluate the incidence of CV AEs and the association with the SCORE assessment and other baseline risk factors. The secondary objectives were to evaluate the role of primary prophylaxis in preventing CV atherothrombotic events.
We identified consecutive adult patients with CML who initiated nilotinib or dasatinib as (Supplemental table 3 ). We stratified patients using a simple score based on positive anamnesis for CV disease and a treatment with 2 ndG TKIs administered as second-line or beyond. Patients with none or one factor were considered to be at standard risk; patients with both factors were considered to be at high-risk of CV AEs. The CV AE incidence was significantly higher in patients with a CML-CV high-risk score, with both risk factors, compared with that in patients with none or one factor (45.9±8.2% vs 16.3±4.4% and 18.7±3.9%, p<0.001) (Figure 1 ).
Atherothrombotic diseases (myocardial infarction, angina, ischemic cerebrovascular events and peripheral vascular disease) were registered in 44 (8.7%) of patients. The 6 atherothrombotic AE incidence was 13.1±2.5%. Considering patients aged ≥60 years with high CML-CV risk score, the atherothrombotic AE incidence was significantly lower in 6 patients who were treated with 100 mg/day of aspirin compared to that in 34 patients who did not undergo primary prophylaxis (0% vs. 58.2±18.9%; p=0.01) (Supplemental Figure   2 ). Aspirine was administered for a median of 54 (range 21-64) and 46 (range 5-64) months to the group with and without CV AEs, respectively. Overall, we also found a trend towards a lower atherothrombotic AE incidence in 10 patients of varying ages with high CML-CV risk score who were treated with 100 mg/day of aspirin compared to that in the 59 patients who did not undergo primary prophylaxis (0% vs. 33.9± 9.5%; p=0.11).
CV AEs represent off-target relevant complications of 2 nd and 3 rdG TKI treatment [6, 7] .
Our study showed that a positive history for CV diseases and treatment with 2 ndG TKIs administered as second-line or beyond was significantly associated with a higher incidence of CV AEs. Indeed, patients with both risk factors showed a 5-year CV-AE incidence of 45.9%, which was significantly higher compared to that in patients with no or only one risk factor. Therefore, we suggest that this simple score (CML-CV total risk=2) represents an easy-to-use and rapid tool to identify patients with an increased risk of developing CV AEs if treated with nilotinib or dasatinib. These patients could benefit from switching to another TKI with a lower CV risk profile (imatinib or bosutinib), avoiding sequential administration The role of aspirin is debatable and no conclusive data have been published thus far. In patients aged ≥60 years with a CML-CV high risk=2 treated with 100 mg/day of aspirin, however, we observed a significantly lower incidence of atherothrombotic AEs compared to 7 that in those without primary prophylaxis. Future prospective studies are needed to further corroborate our preliminary findings.
In conclusion, our findings emphasize the need to personalize prevention strategies based on CV risk factors. Data on the efficacy of primary prophylaxis in patients with high-risk CV-CML score are promising, but need to be confirmed in prospective randomized trials. 2ndGTKI, second-generation tyrosine kinase inhibitor; CML, chronic myeloid leukemia.
